ReviewCancer research2011
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Review in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 125 citations in OpenAlex.
- A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.Blood cancer journal · 2020Trial
- Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.Blood advances · 2020Trial
- Article
- Targeting CD22 for B-cell hematologic malignancies.Experimental hematology & oncology · 2023Review
- Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.Molecular cancer therapeutics · 2022Article
- Recombinant immunotoxins development for HER2-based targeted cancer therapies.Cancer cell international · 2021Review
- Article
- Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.International journal of molecular sciences · 2021Review
- Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells.Oncology letters · 2021Article
- Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells.Frontiers in pharmacology · 2021Article
- Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinomaLiver research (Beijing, China) · 2020Article
- Advances in targeted therapy for malignant lymphoma.Signal transduction and targeted therapy · 2020Review
- Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.Frontiers in immunology · 2020Review
- Article
- Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.Antibody therapeutics · 2019Article
- Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers.Iranian journal of biotechnology · 2018Article
- Bouganin, an Attractive Weapon for Immunotoxins.Toxins · 2018Review
- Domain II ofToxins · 2018Article
- A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.AMB Express · 2017Article
- Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.Oncogene · 2017Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.